Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMGN NASDAQ:MLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMGNImmunoGen$31.23$31.23$3.61▼$31.25$8.32B1.188.78 million shsN/AMLTXMoonLake Immunotherapeutics$21.22-4.2%$18.08$5.95▼$62.75$1.63B1.04871,919 shs1.74 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMGNImmunoGen0.00%0.00%0.00%0.00%0.00%MLTXMoonLake Immunotherapeutics+15.36%+15.48%+21.83%+32.62%-49.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMGNImmunoGen$31.23$31.23$3.61▼$31.25$8.32B1.188.78 million shsN/AMLTXMoonLake Immunotherapeutics$21.22-4.2%$18.08$5.95▼$62.75$1.63B1.04871,919 shs1.74 million shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMGNImmunoGen0.00%0.00%0.00%0.00%0.00%MLTXMoonLake Immunotherapeutics+15.36%+15.48%+21.83%+32.62%-49.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMGNImmunoGen 0.00N/AN/AN/AMLTXMoonLake Immunotherapeutics 2.38Hold$23.8512.38% UpsideCurrent Analyst Ratings BreakdownLatest MLTX and IMGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/9/2026MLTXMoonLake Immunotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.006/8/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.005/12/2026MLTXMoonLake Immunotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/12/2026MLTXMoonLake Immunotherapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$25.00 ➝ $30.005/11/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.003/30/2026MLTXMoonLake Immunotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.003/23/2026MLTXMoonLake Immunotherapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderperform ➝ Outperform$12.00 ➝ $24.00(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMGNImmunoGen$287.61M28.91N/AN/A$0.71 per share43.99MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$4.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMGNImmunoGen-$222.93M-$0.31N/A84.41N/A-25.56%-22.11%-13.53%N/AMLTXMoonLake Immunotherapeutics-$227.32M-$3.87N/AN/AN/AN/A-85.15%-60.52%8/4/2026 (Estimated)Latest MLTX and IMGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026MLTXMoonLake Immunotherapeutics-$0.91-$0.98-$0.07-$0.98N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMGNImmunoGenN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMGNImmunoGen0.135.705.65MLTXMoonLake Immunotherapeutics0.398.608.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMGNImmunoGen90.50%MLTXMoonLake Immunotherapeutics93.85%Insider OwnershipCompanyInsider OwnershipIMGNImmunoGen5.07%MLTXMoonLake Immunotherapeutics12.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMGNImmunoGen277266.26 million252.76 millionNo DataMLTXMoonLake Immunotherapeutics273.61 million64.74 millionOptionableMLTX and IMGN HeadlinesRecent News About These CompaniesMoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering3 minutes ago | finance.yahoo.comMoonLake Immunotherapeutics: Label Upside Drives The Next Leg HigherJune 23 at 9:11 AM | seekingalpha.comMLTX stock clocks best day in over 6 months — what’s driving the investor optimism?June 23 at 3:10 AM | msn.comMoonLake Immunotherapeutics Announces Proposed Public OfferingJune 22 at 4:01 PM | globenewswire.comWhy Is MoonLake Immunotherapeutics Stock Soaring Monday?June 22 at 8:31 AM | benzinga.comMoonLake Highlights Strong Phase 3 Sonelokimab HS ResultsJune 22 at 7:51 AM | tipranks.comMoonLake eyes FDA filing this fall on one-year results for skin treatmentJune 21 at 10:40 PM | seekingalpha.comWhy is MLTX stock rallying nearly 20% overnight?June 21 at 10:40 PM | msn.comMoonLake Immunotherapeutics Reports Week 52 Phase 3 VELA Results Showing Durable Sonelokimab Efficacy in Hidradenitis SuppurativaJune 21 at 5:11 PM | quiverquant.comQMoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026June 21 at 5:00 PM | globenewswire.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Rating of "Hold" by AnalystsJune 21 at 2:09 AM | americanbankingnews.comMLTX stock moves higher as traders position for late-stage trial catalystsJune 18, 2026 | msn.comKristian Reich Sells 50,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) StockJune 18, 2026 | insidertrades.comMoonLake Immunotherapeutics $MLTX Shares Bought by Cormorant Asset Management LPJune 18, 2026 | marketbeat.comMoonLake Immunotherapeutics $MLTX Shares Bought by Rhenman & Partners Asset Management ABJune 13, 2026 | marketbeat.comMoonLake Immunotherapeutics $MLTX Shares Purchased by Fox Run Management L.L.C.June 11, 2026 | marketbeat.comMoonLake shareholders back director, auditor and compensation plansJune 9, 2026 | tipranks.comWhy did MLTX stock rise after-hours today?June 8, 2026 | msn.comMoonLake’s Phase 3 Sonelokimab Trial Reaches Completion in Hidradenitis SuppurativaJune 8, 2026 | tipranks.comMoonLake Immunotherapeutics (MLTX) Price Target Raised to $45 At H.C. Wainwright on FDA ProgressJune 2, 2026 | insidermonkey.comMoonLake Immunotherapeutics (MLTX) Price Target Raised to $45 At H.C. Wainwright on FDA ProgressJune 2, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMLTX and IMGN Company DescriptionsImmunoGen NASDAQ:IMGNImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.MoonLake Immunotherapeutics NASDAQ:MLTX$21.22 -0.94 (-4.24%) Closing price 04:00 PM EasternExtended Trading$21.22 0.00 (-0.02%) As of 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
